<DOC>
	<DOCNO>NCT01950065</DOCNO>
	<brief_summary>Evaluate effectiveness safety iovera device temporary reduction appearance forehead wrinkle .</brief_summary>
	<brief_title>Effectiveness Safety Study Iovera Device Temporary Reduction Appearance Forehead Wrinkles</brief_title>
	<detailed_description />
	<criteria>Age 18 65 year Subject forehead wrinkle rating Investigator/designee least `` 2 '' full contraction 5point Wrinkle Scale ( 5WS ) rat study Investigator , , upon physical manipulation/separation skin , demonstrate reduction wrinkle severity Subject glabella wrinkle rating Investigator/designee least `` 1 '' full contraction 5point Glabella Scale ( 5GS ) Subject least 2 point difference rest dynamic forehead wrinkle score use 5point Wrinkle Scale ( 5WS ) rat Investigator/designee Subject Fitzpatrick Skin Type I , II , III , IV ( see Error ! Reference source find . ) Subject understand commits comply study requirement Subject good general health free condition could impair either complete study participation evaluation forehead wrinkle rating Subject willing able give write informed consent Subject clot disorder coagulopathy require regular use anticoagulant and/or antiplatelet therapy ( e.g. , warfarin , clopidogrel , etc . ) Subject use aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) within seven ( 7 ) day prior screen use device Subject prior surgery alters subcutaneous anatomy target treatment site Subject undergone another surgical cosmetic procedure botulinum toxin injection level zygoma ( cheekbone ) within past six ( 6 ) month prior screen Subject rest wrinkle score `` 3 '' high 5WS rat study Investigator Subject actively elevate forehead rest Subject treat filler list Error ! Reference source find . temple forehead area time interval specify prior screen Subject following condition : Dermatochalasis &lt; 2mm lid margin look straight ahead Excessive skin laxity/skin age Asymmetry upper face History facial nerve palsy Eyebrow eyelid ptosis History neuromuscular disorder Chronic dry eye symptom Allergy intolerance local anesthetic agent ( e.g. , Lidocaine ) Use narcotic medication chronic pain condition Other clinically significant local skin condition ( e.g. , skin infection ) target treatment site Any physical psychiatric condition Investigator 's opinion would prevent treatment adequate study participation Chronic medical condition Investigator 's opinion would affect study participation ( diabetes , hepatitis , HIV , etc . ) Known diagnosis cryoglobulinemia , paroxysmal cold hemoglobinuria , cold urticaria Subject know noncompliant unlikely comply requirement study protocol ( e.g. , due alcoholism , drug dependency , mental incapacity ) opinion Investigator Fitzpatrick Skin Type V VI ( see Table 3 ) Subject currently enrol investigational drug , biologic device study could affect safety effectiveness wrinkle treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>